CN109846040A - Use of balsam pear seed oil for preparing anti-body fat forming preparation - Google Patents
Use of balsam pear seed oil for preparing anti-body fat forming preparation Download PDFInfo
- Publication number
- CN109846040A CN109846040A CN201811635899.9A CN201811635899A CN109846040A CN 109846040 A CN109846040 A CN 109846040A CN 201811635899 A CN201811635899 A CN 201811635899A CN 109846040 A CN109846040 A CN 109846040A
- Authority
- CN
- China
- Prior art keywords
- seed oil
- melon seed
- bitter melon
- adipogenesis
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000302512 Momordica charantia Species 0.000 title claims abstract description 96
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 235000009812 Momordica cochinchinensis Nutrition 0.000 title abstract description 11
- 235000018365 Momordica dioica Nutrition 0.000 title abstract description 11
- 235000015112 vegetable and seed oil Nutrition 0.000 title abstract 4
- 230000011759 adipose tissue development Effects 0.000 claims abstract description 34
- 239000010507 melon oil Substances 0.000 claims description 75
- 239000002775 capsule Substances 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 24
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 13
- 229960002748 norepinephrine Drugs 0.000 claims description 12
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 12
- 101800001586 Ghrelin Proteins 0.000 claims description 8
- 102000012004 Ghrelin Human genes 0.000 claims description 8
- -1 carrier Substances 0.000 claims description 8
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 101150022052 UCP1 gene Proteins 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000010603 pastilles Nutrition 0.000 claims description 3
- 229920001592 potato starch Polymers 0.000 claims description 3
- 229940100486 rice starch Drugs 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 230000001055 chewing effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 abstract description 57
- 230000000694 effects Effects 0.000 abstract description 17
- 230000003647 oxidation Effects 0.000 abstract description 15
- 238000007254 oxidation reaction Methods 0.000 abstract description 15
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 10
- 239000000194 fatty acid Substances 0.000 abstract description 10
- 229930195729 fatty acid Natural products 0.000 abstract description 10
- 150000004665 fatty acids Chemical class 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 8
- 208000008589 Obesity Diseases 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 235000020824 obesity Nutrition 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000007614 genetic variation Effects 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000005037 parasympathetic nerve Anatomy 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 50
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 18
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 18
- 238000005259 measurement Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000004003 subcutaneous fat Anatomy 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000012545 processing Methods 0.000 description 11
- 238000000540 analysis of variance Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000004006 olive oil Substances 0.000 description 10
- 235000008390 olive oil Nutrition 0.000 description 10
- 230000000241 respiratory effect Effects 0.000 description 10
- 239000013589 supplement Substances 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000005265 energy consumption Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000037323 metabolic rate Effects 0.000 description 8
- AOMXURITGZJPKB-ZETCQYMHSA-N (2s)-2-amino-5-[(n'-propylcarbamimidoyl)amino]pentanoic acid Chemical compound CCCN=C(N)NCCC[C@H](N)C(O)=O AOMXURITGZJPKB-ZETCQYMHSA-N 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- CUXYLFPMQMFGPL-FWSDQLJQSA-N alpha-Eleostearic acid Natural products CCCCC=CC=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-FWSDQLJQSA-N 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 5
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- IXLCRBHDOFCYRY-UHFFFAOYSA-N dioxido(dioxo)chromium;mercury(2+) Chemical compound [Hg+2].[O-][Cr]([O-])(=O)=O IXLCRBHDOFCYRY-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 229960004488 linolenic acid Drugs 0.000 description 5
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 235000009815 Momordica Nutrition 0.000 description 3
- 241000218984 Momordica Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108010088847 Peptide YY Proteins 0.000 description 3
- 102100029909 Peptide YY Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000007156 Resistin Human genes 0.000 description 3
- 108010047909 Resistin Proteins 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- CUXYLFPMQMFGPL-WPOADVJFSA-N (9Z,11E,13E)-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C/CCCCCCCC(O)=O CUXYLFPMQMFGPL-WPOADVJFSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 241000353135 Psenopsis anomala Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000020795 whole food diet Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102100031301 Brain mitochondrial carrier protein 1 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000777114 Homo sapiens Brain mitochondrial carrier protein 1 Proteins 0.000 description 1
- 101000777117 Homo sapiens Mitochondrial uncoupling protein 4 Proteins 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 1
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 1
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 description 1
- 102100031307 Mitochondrial uncoupling protein 4 Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- BBFQZRXNYIEMAW-UHFFFAOYSA-N aristolochic acid I Chemical compound C1=C([N+]([O-])=O)C2=C(C(O)=O)C=C3OCOC3=C2C2=C1C(OC)=CC=C2 BBFQZRXNYIEMAW-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 238000011871 bio-impedance analysis Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical class CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000010159 dioecy Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000010462 extra virgin olive oil Substances 0.000 description 1
- 235000021010 extra-virgin olive oil Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The invention provides the use of balsam pear seed oil for preparing an antibody adipogenesis preparation, which is characterized in that an effective dose of balsam pear seed oil is added to a required individual; wherein the individual has a particular genetic variation for obesity. The balsam pear seed oil can not only increase the content of high-density cholesterol, increase calorie expenditure, increase fatty acid oxidation and inhibit body fat formation, but also can not cause the side effects of liver injury, sympathetic nerve and parasympathetic nerve over activation after being taken by a user, thereby being capable of developing safe and effective body fat reducing health-care food.
Description
Technical field
The present invention relates to the purposes of vegetable fat, in particular to bitter melon seed oil is for inhibiting the purposes of body fat formation.
Background technique
With development of human civilization, the liveliness proof kenel static increasingly of many people, along with exercise habit is insufficient and
Universal, the fat healthy public enemy for just like having become countries nowadays government and society's effort confrontation of high heat food, world health
Obesity was more defined as a kind of disease in 1997 by tissue；Between past 20 years, population in the world obesity ratio is grown up with multiple, at
The average height of people only increases by 1%, but average weight and BMI increase separately 15 and 11%, according to data statistics, in 2008 years
Global adult existing 1,500,000,000 populations are fallen in overweight scope, and are estimated the overweight population in the whole world and will be increased year by year.In addition, fertile
Fat is not only merely to influence figure and appearance, and the risk of other chronic diseases, such as diabetes, angiocarpy are more suffered from along with raising
Disease, arthritis, with certain cancers (carcinoma of endometrium, breast cancer and colon cancer etc.), have the country at 65% population place in the world
Its is overweight lethality is far more than because underweight and lethal.Therefore, prevention heart and brain are become for fat early prevention and control
One of vascular diseases and tumorigenic main project.
Fat why to become " epidemic disease ", making a thorough investigation is the difference mistake of mankind ancestors source environment and modern environment
Greatly, we can not reply life style certainly, therefore cultivate entire society and personal health and the life that can continue forever
Kenel is only the task of top priority.In addition, fat generality also drives scientific research, medical field is for fat cell physiology in recent years
Understanding have rapid progress, while also using biotechnology or exploitation drop body fat function ingredient, with postpone human obesity population increasing
In addition trend.
Drop body fat product and method on current market is numerous, can be divided into following a few classes: though liposuction can subtract one
A little fat, but due to there is no practical solution obesity, it is likely that it will appear rebound, and there is the wind that complication occurs
Danger；The diarrhea fat reducing method of weight-reducing owned by France in fierce formula can only subtract the nutrition such as moisture and protein, but actually fat is still deposited
In vivo, it be easy to cause metabolic disturbance for a long time, causes endocrine disorder；Diet fat reducing method be by willpower control appetite, if
Willpower deficiency is difficult to persistently, and is easy to appear psychological problems, once restoring diet, is easier to rebound；Chinese medicine acupuncture is massaged and fortune
Though dynamic weight-reducing methodological science, curative effect is reliable, need to there is certain condition and strong willpower, it is difficult to persevering；Drug
Fat reducing method, though being suitable for certain morbid oberities individual, toxic side effect is big, seems to have been cited as the Mei Di of banning drugs to open up
(Mediator), sibutramine (Sibutramine) and aristolochic acid etc.；In addition, other seem that enteron aisle is inhibited to digest and assimilate
Drug orlistat (Orlistat), or increase the ephedrine and thyroxine of energetic supersession, it takes for a long time and easily causes blood pressure
The illnesss such as raising, arrhythmia cordis, heart disease, metabolic function disorder, fat soluble vitamin absorption be bad, although weight-reducing is made
With significant, but its apparent side effect makes one to hang back.
People all over the world take 3,60000000000 beauty to lose weight on drug, health food and exercise program
Member.In Taiwan, there are about the weight of 1/3 male fall in overweight range, 1/5 the weight of women male fall in overweight model
It encloses, along with domestic young woman one is to being keen to lose weight, rough estimate Taiwan loss of weight market one is over 60000000000 yuan, it can thus be appreciated that weight-reducing
Market it is vast.However, as described above, drop body fat product and method are all difficult to reach satisfactory results at present, and have strong
Doubt in health authenticates a variety of products for having and being not easy to be formed body fat although defending the portion of clothes and having, and the ingredient of those products is more
Based on catechin, dietary fiber or Structure grease (structured lipids), it is rare other by rigorous and scientific verifying,
The food composition of novel safety.
In addition, it is considered that it is fat other than related to the environmental factors such as diet posteriority, living habit, it is congenital
Gene genetic is also to lead to fat one of reason.It is pointed out according to research, there are many genes will affect appetite, new old generation for human body
It thanks and Fat Distribution etc., and the genotypic difference between Different Individual will lead to certain people with the easy to be fat of familial genetic predisposition
Constitution.
Single nucleotide polymorphism (the single nucleotide of fat phenotype and specific mankind's ob gene
Polymorphism, SNP) it is related；For example, uncoupling protein (uncoupling protein, UCP) is a kind of wire body inner membrance
Albumen, this protein can eliminate the oxygen that a cross-film proton concentration for wire body inner membrance two sides is poor, and order is driven using proton concentration difference
Change Phosphorylation events to slow down, inhibits the normal generation of atriphos (ATP), directly convert thermal energy for energy and discharge, and by
By the heat production of participation adipose tissue, decomposes and improve metabolic rate to adjust the constant of body fat.Be currently known UCP1, UCP2,
Five kinds of uncoupling protein of UCP3, UCP4, UCP5, wherein UCP1 is expressed in brown adipose tissue, and major function is to participate in life
Heat promotes energy consumption, therefore can weaken brown fat activity when UCP1 variation, and then lead to fat generation；In addition, β 3-
Adrenocepter (β 3AR) is a kind of film surface receptor that G-protein couples, and has the weight for adjusting lipolysis and energy consumption
Act on, be mainly distributed on brown adipose tissue, the overweight people with β 3AR genetic mutation because internal β 3AR activity reduce,
Interior fat decomposition and energy production are slowed down, basal metabolic rate reduces, thus accelerates fat generation.
Thus, since aforementioned drop body fat product or method can not all carry out effectively for the variation of specific ob gene
Body fat effect is dropped, and consumer is not only unable to get satisfactory drop body fat effect, more likely in the case where blindness use
Cause side effect, affects human health.Therefore industry there's no one who doesn't or isn't can urgently be furtherd investigate and develop one kind and can be directed to
The individual of specific ob gene type has drop body fat, postpones the effect of body fat generation, while taking into account human-body safety again, does not have secondary work
Novel effective component.
Balsam pear scientific name Momordica charantia also known as balsam pear, bright and beautiful lichee, balsam pear, leprosy grape, belong to Curcurbitaceae
(Cucurbitaceae), Momordica (Momordica), is Asia people daily consumption vegetables, and producing region includes Taiwan, South China
Side, Southeast Asia and Okinawa Japan.The balsam pear annual output about 3 in Taiwan, it is 000 tonne, (including dioecism momordica root series) various in style, it is Taiwan
One of most common melon-fruit-like vegetable.Balsam pear fruit is berry, belongs to cold, nontoxic, Chinese pharmacology records that clear heat is antipyretic, clears away heart-fire
Improving eyesight, removing toxic substances and kidney tonifying profit spleen and other effects, there is antitumor, antiviral, anti-inflammatory, hypoglycemic or reducing blood lipid etc. to control for research now
Treat potentiality.Balsam pear hypoglycemic function is also largely ground by western scientist note that having in relation to its mechanism of action and functional component
Study carefully.Only, compared to hypoglycemic effect, balsam pear is less for the correlative study for dropping body fat effect, though some studies pointed out that bitter melon seeds
In oil conjugation linolenic acid (cis9, trans11, trans13-conjugated linolenic acid, c9, t11,
T13-CLN) there is in mouse experiment the effect of drop body fat, but do not have yet further for the effect of the ob gene in human body
Correlative study.
Summary of the invention
Thus, in view of this, the present inventor is examining various possible solutions with great concentration for the problem of above-mentioned located by prior art
Certainly scheme, after a large amount of analysis experimental study, and then find bitter melon seed oil have for obese individuals slow down body fat and
The effect of dropping body fat has especially for the individual with specific ob gene variation and excellent slows down the benefits of body fat is formed
Fruit can be used for developing safe and effective drop body fat health food.
In other words, the present invention can provide the purposes that a kind of bitter melon seed oil is used to prepare antibody Adipogenesis preparation, be
The bitter melon seed oil of an effective dose is bestowed to required individual；Wherein the individual makes a variation with specific ob gene.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, aforementioned effective dose system is between 0.01 to 0.5 gram of bitter melon seed oil/individual kilogram weight/day range；Preferably between
0.01 to 0.4 gram of bitter melon seed oil/individual kilogram weight/day range；It is more preferably public between 0.01 to 0.3 gram of bitter melon seed oil/individual
The range in jin weight/day；Particularly good is between 0.01 to 0.2 gram of bitter melon seed oil/individual kilogram weight/day range；Most preferably between
0.01 to 0.1 gram of bitter melon seed oil/individual kilogram weight/day range.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein the bitter melon seed oil contain special ratios conjugation linolenic acid (conjugated linolenic acid,
CLN)；The conjugation linolenic acid can be α-eleostearic acid (α-eleostearic acid；α-ESA).
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein (α-eleostearic acid of the bitter melon seed oil containing 40wt% or more；α-ESA), preferably contain α-eleostearic acid.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein the specific ob gene be UCP1 gene or β 3ADR gene；The preferably AA type or β 3ADR of UCP1 gene
The CC type of gene.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein the bitter melon seed oil is able to suppress the generation of hungry plain (Ghrelin).
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein the bitter melon seed oil can promote adrenaline (adrenaline) and norepinephrine
(noradrenaline) generation.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, wherein the individual be the mankind.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, the antibody Adipogenesis preparation further include additive, carrier, excipient, diluent and they combination in extremely
Few one kind.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, the content of the bitter melon seed oil is the range 5%~100%；Preferably 10%~100% range；More preferably
In 20%~100% range；Particularly good is the range 30%~100%；Most preferably 30%~100% range.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, the excipient is by lactose, sucrose, mannitol, sorbierite, cornstarch, wheaten starch, rice starch, potato
Starch, gelatin, bassora gum, and combinations thereof in any one or more constituted.
Specific embodiment can provide a kind of bitter melon seed oil and be used to prepare antibody Adipogenesis preparation one of according to the present invention
Purposes, the dosage form system of the antibody Adipogenesis preparation be selected from solution, emulsion, suspension, powder, pastille, pill, mouth containing ingot,
It is any in tablet, chewing glue and capsule.
Technical solution provided by the invention has the benefit that
It was found that bitter melon seed oil has obese individuals the effect of slowing down body fat and drop body fat, especially for spy
The individual for determining ob gene variation has the excellent effect for slowing down body fat formation, can be used for developing safe and effective drop body fat
Health food.
Detailed description of the invention
Fig. 1 be the present invention in embodiment experimental group compared with the fatty acid oxidation amount incrementss of control group figure.
Specific embodiment
Hereinafter, enumerate different specific embodiments for state sample implementation of the invention and more fully hereinafter describe and illustrate,
It is apparent to keep spirit of the invention more complete with content；It should however, having usually intellectual in the skill
The clear present invention is not only restricted to these examples certainly, can also be reached using other same or impartial function with sequence of steps
At the present invention.
Herein, the meaning of science and technology vocabulary used herein with have in the technical field of the invention it is usual
Skill understands identical as usual meaning.In addition, in the case of getting along well context conflict, odd number used in this specification
Noun covers the complex number type of the noun；And also cover the singular type of the noun when used plural noun.
Herein, " antibody Adipogenesis " system means that said preparation has to inhibit, reduce and/or adjust and controls body fat
The function of formation.
Herein, for the numerical value and parameter to define the scope of the invention, substantially inevitably containing because a
Standard deviation caused by other test method, thus indicated with rough quantitative value mostly, however in specific embodiment then
The correlation values of presentation reported as precisely as possible.Herein, " about " usually view has usual knowledge in the technical field of the invention
Depending on the considerations of person, generally mean that representing actual numerical value falls within the acceptable standard error of average value, for example, the actual number
Value is within ± 10%, ± 5%, ± 1% or ± the 0.5% of a certain number value or range.
In the embodiment of this paper, all data all with STATA software, version 13 (Stata Corp.,
California, USA) analysis.At 4 weeks, 8 weeks, 12 weeks of experimental group and control group and baseline (0 week) variable quantity difference with
Co-variation heteromerism (Covariance) statistical compares, and with duplicate measurements variance (Repeated measure ANOVA) system
Meter mode analyzes comparing for group difference during processing.Two groups of polymorphisms and gender frequency distribution is with chi-
The analysis of square test statistical.All data are all with mean ± SD and mean difference (95%confidence
Interval it) indicates.Baseline and delta fat oxidation compares two group differences with t-test.As p < 0.05
Indicate that there is significant difference.
One of according to the present invention state sample implementation, the antibody Adipogenesis preparation of the oil containing bitter melon seed of the present invention can be with figuration
Agent administration or administration in the case where no excipient together.Also, can also be by the antibody fat shape of the oil containing bitter melon seed of the present invention
Become the pastille for including various adjuvants, various disintegrating agents, particle binder or lubricant and forming solid dosage at pharmaceutical formulation.
In addition, in one embodiment, lactose or high molecular weight polyethylene glycol also can be used.It, can be in addition, depending on depending on the circumstances or the needs of the situation
Further it is used to improve the coating or coating of any active pharmaceutical ingredient rate of release, such as Enteric coatings etc..At other
Example in, the antibody Adipogenesis preparation of the oil containing bitter melon seed of the present invention, which is also possible to be formulated, becomes micro- rouge body structure or tool
Bionical interstitial system structure, or can be filled in soft or hard gelatin capsule or can be encapsulated in the pack of bioerodible
Interior particle.
Also, in the present invention, pharmaceutically acceptable excipients mean can it is compatible with other compositions in pharmaceutical formulations and with
Organism compatibility person, for example, encapsulation materials or such as sorbefacient, antioxidant, binder, buffer, covering, coloring
Agent, diluent, disintegrating agent, emulsifier, replenishers, filler, flavoring agent, moisturizer, lubricant, fragrance, preservative, propulsion
The various additives of agent, releasing agent, fungicide, sweetener, solubilizer, wetting agent and its mixture etc..In addition the additive
Can be health nutrient ingredient, wholefood ingredient, and combinations thereof one of kind, for example, the health nutrient ingredient can be with
Be citric acid, vitamin, Amino acid, minerals or other beneficial to human health ingredient；And the wholefood ingredient can be
From the ingredients such as vegetables and fruits or animal.
It is suitable for the adjuvant that the present invention uses, for example, it is, for example, possible to use microcrystalline cellulose, calcium carbonate, di(2-ethylhexyl)phosphates
Calcium or glycine.It is suitable for the disintegrating agent that the present invention uses, for example, it is, for example, possible to use starch, alginic acid or specific silicon
Hydrochlorate.Be suitable for the particle binder that uses of the present invention, for example, it is, for example, possible to use polyvinylpyrrolidone, sucrose,
Gelatin or Australian gum (acacia).It is suitable for the lubricant that the present invention uses, for example, it is, for example, possible to use stearic acid
Magnesium, lauryl sodium sulfate or talcum etc..It is suitable for the excipient that the present invention uses, for example, it is, for example, possible to use creams
Sugar, sucrose, mannitol, sorbierite, cornstarch, wheaten starch, rice starch, potato starch, gelatin, bassora gum etc..
In some embodiments, the antibody Adipogenesis preparation of the oil containing bitter melon seed of the present invention is to be formulated to become to be suitble to
Oral liquid dosage form, for example, suspension for oral use, emulsion, microemulsion and/or specific remedy (elixirs).In this liquid
In the case where body dosage form, the active constituent of the antibody Adipogenesis preparation of the oil containing bitter melon seed of the present invention can further with it is various
Sweetener or flavouring agent, colorant or dyestuff are formulated together, can also be added if necessary emulsifier and/or suspending agent or such as
The diluents such as water, alcohol, propylene glycol, glycerol or the buffer for maintaining pH value.
Furthermore it in some embodiments, can also further add alcohols, carboxymethyl cellulose dispersing agent, boundary
Face activating agent, emulsifier or other similar object.
In addition, the antibody Adipogenesis preparation of oil containing bitter melon seed of the invention can also will be contained in some embodiments
Liquid formulations be filled in soft capsule to use.
In order to keep the narration of this disclosure more detailed with it is complete, below for state sample implementation of the present invention and specific implementation
Example proposes illustrative description；But this not implements or uses the unique forms of the specific embodiment of the invention.Contain in embodiment
The feature of multiple specific embodiments and method and step and its sequence to these specific embodiments of construction and operation are covered.So
And it can also reach identical or impartial function and sequence of steps using other specific embodiments.
Firstly, illustrating the operating method for the items detection that embodiments of the present invention use.
" position and body form "
Measure height, weight, waistline, the hip circumference, blood pressure of each subject, and the BMI that converts, waist-to-hipratio.In addition, body composition with
Electric-resistivity method measurement；By fat meter in the way of bioelectrical impedance analysis, using weak current by human body, by musculature and rouge
The difference of fat tissue resistance, and then calculate the content ratio of the muscle in human body and fat.
" blood analysis inspection "
In the state of subject's fasting 12 hours or more, the venous blood for extracting subject carries out biochemical blood inspection
It surveys；Detection project includes: serum alanine transaminase (GPT) (inter-assay CV < 5%), serum bran oxalic acid turn amido ferment
Plain (GOT) (inter-assay CV < 5%), total cholesterol (Cholesterol) (inter-assay CV < 2%), three acid are sweet
It is grease (TG) (inter-assay CV < 2%), high-density lipoprotein cholesterol (HDL-C) (inter-assay CV < 2%), low
Density lipoprotein-cholesterol (LDL-C) (inter-assay CV < 2%), fasting blood-glucose (fasting blood glucose)
(inter-assay CV < 5%) and insulin (fasting insulin) (inter-assay CV < 2%) are with commercial reagent
Group (Roche, USA) measurement.
In addition blood hormone and cell factor (cytokines) be such as: adrenaline (Adrenaline) (inter-
Assay CV < 5%), noradrenalin (Noradrenaline) (inter-assay CV < 5%), hungry element
(Ghrelin) (inter-assay CV < 5%) and polypeptide-YY (Peptide YY) (inter-assay CV < 15%) are with city
Sell reagent set (Elabscience, China) measurement；Cytohormone Il-6 (inter-assay CV < 10%) and neoplasm necrosis
The factor-α (TNF-α) (inter-assay CV < 10%) is with commercial reagent group (eBioscience, USA) measurement；Thin voxel
(Leptin) (inter-assay CV < 5%) and phylaxin (Resistin, inter-assay CV < 10%) are with commercial reagent
Group (Peprotech, USA) measurement.
" identification of the SNP gene type of UCP1 (rs1800592) and β 3AR (rs4994) "
The whole blood of subject is collected, then with EDTA heparin tube with commercial reagent group InstaGene (Bio-Rad, Canada)
DNA extraction stores -80 DEG C, then with TaqMan SNP genotyping analysis UCP1 (rs1800592) and β 3AR (rs4994)
SNP gene type.
" respiratory quotient analysis "
Subject after fasting 12 hours, the awake rest 30 minutes of sitting quietly to carrying out after sixty minutes, measure each organ and
System carries out most basic physiological activity, the metabolisable energy of required consumption.It is first rectified an instrument using preceding every time, subject puts on
The measurement for starting ten minutes after mask, breathes during measurement and gas venting one's pent-up feelings is calculated separately, using oxygen concentration (VO2) and
Gas concentration lwevel (VCO2) calculates respiratory quotient (respiratory quotient, RQ), rest metabolic rate (resting
Metabolic rate, REE), fatty acid oxidation amount (fat oxidation).Measuring instrument is indirect
calorimeter(VIASYS Healthcare,Yorba Linda,CA,USA)。
The calculation formula of respiratory quotient (RQ) is as follows:
RQ=VCO2/VO2
Because metabolism food type is different, energy consumption source will be seen that by the numerical value of respiratory quotient: fat, protein and carbon
Hydrate, the ratio being utilized；For example, when RQ is about 1,100% system of energy is supplied by carbohydrate；When RQ about
When being 0.7, energy source is supplied by fat；When RQ is about 0.8, energy source is supplied by protein；When RQ is about
When 0.8-0.85, energy source is by Combination food supply.
The calculation formula of rest metabolic rate (REE) is as follows:
REE (Kcal)=[(3.94 × VO2)+(1.106 × VCO2)] × 1.44
The calculation formula of fatty acid oxidation amount (fat oxidation) is as follows:
Fat oxidation (mg/min)=1.689 × [VO2 (L/min)-VCO2 (L/min)]
" diet record in three days "
Subject shoots eaten food using mobile phone and sends photo to nutritionist, calculates the heat of feed in one day by nutritionist
Amount and three nutritious elements content.
Then, hereby lift the preferred embodiments of the invention, and cooperate schema to do further detailed description is as follows.
" preparing bitter melon seed oil "
It is that 10% bitter melon seed below is placed in extraction tank by moisture content, with pressure be 10MPa~60MPa, temperature is
20 DEG C~60 DEG C, the condition that flow velocity is 30~60g/mL, extraction time is 6-8 hour, are extracted using supercritical carbon dioxide fluid
Take out the thick extraction object of bitter melon seed oil.
The bitter melon seed known to after the bitter melon seed oil that above-mentioned supercritical carbon dioxide extraction goes out is analyzed with GC/MS
α-eleostearic acid content in oil beBetween.
" embodiment "
Bitter melon seed oil obtained by above-mentioned preparation example is filled into capsule, contains 500mg in each bitter melon seed oil capsule
Bitter melon seed oil；In addition, the virgin oil (extra virgin olive oil) for preparing equivalent is filled to appearance and the hardship
It is used as a control group in the identical capsule of melon seeds oil capsule.
Then, testee is randomly divided into experimental group and two groups of control group, every group of each has age is between 20 to 64 years old
28 subjects (male 15, women 13)；The BMI of all subjects all (or waistline male > 90cm, female 24 or more
Property > 80cm), and except condition is the first type, the diabetic of second type or use of exogenous insulin, is unable to control seriousness blood
High (systolic pressure > 180mmHg, diastolic pressure > 100mmHg) is pressed not receive the hypertensive patient of the treatment of drug for hypertension, have
The medical histories such as liver function damage, impaired renal function, cardiovascular disease, headstroke, cancer, before and after capital operation, severe psychiatric or
Neuropathy person, the person that can not cooperate with research step assert through doctor and are unable to complete this researcher.The subject during test
Diet and amount of exercise suggestion control deactivate the related production of any weight-reducing (supplement capsule front and back is all) as usual
Product.
The subject of experimental group daily bitter melon seed oil capsule, breakfast, lunch and dinner edible tri before meals, one day nine edible, and right
According to subject's then daily olive oil capsule of equivalent of group；Experimental group and control group are all taken 12 weeks.
Before on-test, first collected with questionnaire by basic documents such as formula person's age, gender, history of disease；Then, it is opening
Begin to measure weight, body fat, waistline, blood pressure and electrocardiogram respectively when (0 week), interim (4 weeks and 8 weeks) and end (12 weeks)；?
Blood drawing carries out blood analysis inspection respectively when on-test (0 week), interim (4 weeks) and end (12 weeks), and makees 3 days diet and record
Record；Respiratory quotient (RQ) analysis is carried out when on-test (0 week) and end (12 weeks) respectively.Fasting is needed before the above inspection.In addition, adopting
Blood sample when collecting on-test (0 week) carries out identified for genes.
Two groups of subject's male to female ratio at 0 week, weight, position, body fat, blood biochemical genetic marker, blood pressure, heartbeat,
RQ, VO2, VCO2 and REE result are all without significant difference, two groups of any parameter values all indifferences when starting.In addition, three days drink
Food has recorded the diet of 0wk, 4wk, 12wk, and calorie intake is each between analyzing two groups with unpair student t-test
Time point, calorie intake was also without significant difference before and after being analyzed in each group with pair student t-test all without significant difference.It is aobvious
There is confidence level if showing subsequent analytical control result there were significant differences.
" influence of the bitter melon seed oil for weight, position and body fat "
The weight (Kg), BMI value of subject, waistline (cm), waist-to-hipratio, body fat rate (%), body in experimental group and control group
After rouge weight (Kg), interior fat weight (Kg) and subcutaneous fat weight (Kg) are subject to average computation respectively, by records of values in table 1, divide
Each group is analysed with the variation for taking Capsules Time increase.
Table 1
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks, 8 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week.
Analyze result from the repeated measure of above-mentioned table 1: subject in control group is with taking olive
The time of oil capsule increases and puts on weight, BMI, body fat rate, body fat are heavy, abdominal fat weight and subcutaneous fat are heavy (p < 0.05),
Waist-to-hipratio is then without significant difference；Subject in experimental group only increases body fat rate (p < 0.05), and weight, BMI, body fat weight, waist
Stern ratio, interior fat weight and subcutaneous fat weight are then without significant difference；The waistline of other two groups of subjects all significantly reduce (p <
0.05)。
" bitter melon seed oil is for blood biochemical genetic marker, blood pressure and the influence of heartbeat "
After the blood biochemical genetic marker of subject in experimental group and control group is subject to average computation respectively, by records of values in
Table 2.
Table 2
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week.
Two groups of liver functions during test (GOT, GPT), blood lipid (cholesterol, TG, HDL-C, LDL-C), fasting blood
Sugared (Glucose AC), insulin (Insulin), blood pressure, heartbeat numerical value are all normal, and two groups all without significant difference.Then, with
Repeated measure is analyzed, the high-density lipoprotein (HDL-C) of the subject in experimental group and diastolic pressure (Dbp) with
Take bitter melon seed oil capsule time increase and increase (p < 0.05), remaining detection project is all without significant difference.Although diastole
Pressure is improved with the time for taking bitter melon seed oil capsule, but still within normal range value (50~90mmHg), hardship is taken in display
Melon seeds oil will not be cardiovascular to human body and liver causes to bear, additionally it is possible to the content for improving high-density lipoprotein (HDL-C), for
Arteries has the function of protection.
" influence of the bitter melon seed oil for the blood cell factor and hormone "
The blood cell factor of subject in experimental group and control group and hormone content are subject to average computation respectively
Afterwards, by records of values in table 3.
Table 3
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week.
The result as recorded in above-mentioned table 3 is it is found that the starvation plain (Ghrelin) of experimental group and control group during test contains
Amount is all without significant difference, but when plain (Ghrelin) content of starvation of the subject in experimental group is with bitter melon seed oil capsule is taken
Between increase and reduce.Hungry element (Ghrelin) is hormone of the stomachial secretion to blood, can adjust energy balance, pass through when hungry
It is conducted by blood to hypothalamus and is stimulated appetite, increase food-intake；In addition, also some studies pointed out that muroids to inject Ghrelin, do not increase
The phenomenon that still visible fat is accumulated under the situation of its appetite；Therefore, display takes bitter melon seed oil and is able to suppress hungry element
(Ghrelin) generation, and then the effect with appetite-suppressing.
The adrenaline (adrenaline) and norepinephrine of experimenter in control group and experimental group
(noradrenaline) content all increases as the time for taking bitter melon seed oil capsule and olive oil capsule increases during test
Add.The catecholamines of adrenaline (adrenaline) and norepinephrine (noradrenaline) etc.
(catecholamines) being noted can stimulate central nervous system (sympathetic nervous system) to promote life
Thermal response (thermogenesis) and then increase heat expenditure, reduce body fat accumulation；Have report and points out that olive oil can promote kidney
Upper parathyrine and norepinephrine secretion, embodiments of the present invention show that bitter melon seed oil can also promote adrenaline
(adrenaline) and the generation of norepinephrine (noradrenaline).
Also, polypeptide-the YY (Peptide YY) of the subject in control group and experimental group, thin voxel (Leptin) and resistance
The content of plain (Resistin) is unchanged with the time of processing all without significant difference.Show bitter melon seed oil for polypeptide-YY
The generation of (Peptide YY), thin voxel (Leptin) and phylaxin (Resistin) do not influence.
" influence of the bitter melon seed oil for energy consumption "
By the oxygen concentration (VO2) and gas concentration lwevel (VCO2), respiratory quotient of the subject in experimental group and control group
(respiratory quotient, RQ), rest metabolic rate (resting metabolic rate, REE), fatty acid oxidation amount
After (fat oxidation) is subject to average computation respectively, by records of values in table 4.
Table 4
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week；
* it indicates P < 0.05, is statisticallyd analyze with pair t-test with 0 week in group with 12 weeks compared with
By above-mentioned table 4 it is found that after taking bitter melon seed oil capsule and olive oil capsule 12 weeks respectively, experimental group it is tested
The respiratory quotient (RQ) of person is down to 0.077 from 0.082, and after the subject of display experimental group takes bitter melon seed oil, energy consumption is come
The respiratory quotient that source is gradually turned the subject that control group is reviewed from fatty acid by Combination food is still maintained at 0.081 to 0.083 left side
The right side is still using Combination food as its energy consumption source after the subject of display control group takes olive oil.Also, real
Test oxygen uptake (VO2), carbon dioxide output (VCO2) and the rest metabolic rate (REE), fatty acid oxidation amount of the subject of group
(fat oxidation) all has increase as the time of supplement bitter melon seed oil capsule increases.In addition, with unpair t-test
Statistical analysis compares the knots modification of the intervention 12 weeks of control group and experimental group, and control group and the knots modification of experimental group is drawn
In Fig. 1；Fatty acid oxidation amount incrementss (Delta fat oxidation) as shown in Figure 1 compare figure it is found that experimental group by
Fatty acid oxidation amount incrementss of the examination person after 12 weeks are significantly higher than the subject (p < 0.05) of control group.
It is thus possible to confirm: bitter melon seed oil has the ability for increasing energy consumption, and takes the system of bitter melon seed oil
Using fatty acid as energy consumption source.
" influence of the bitter melon seed oil for SNP gene type "
It is found that having 13 AA types for belonging to UCP1 (rs1800592) in experimental group, having 4 after the identification of poba gene type
Belong to the AG type of UCP1 (rs1800592) and there are 11 GG types for belonging to UCP1 (rs1800592)；There are 10 in control group
Belong to the AA type of UCP1 (rs1800592), there are 12 AG types for belonging to UCP1 (rs1800592) and there are 6 to belong to UCP1
(rs1800592) GG type.In addition, having 23 TT types for belonging to β 3AR (rs4994) in experimental group and thering are 5 to belong to β 3AR
(rs4994) CC type；There are 22 TT types for belonging to β 3AR (rs4994) in control group and there are 6 to belong to β 3AR (rs4994)
CC type.
Then, each gene type of SNP of two groups of UCP1 and β 3AR gene is analyzed with chi-square test statistical
Occurrence frequency, each gene type sample of two groups of UCP1 (rs1800592) or β 3AR (rs4994) polymorphism
Size is not significantly different (p > 0.05), if indicating that the subsequent analysis parameter with gene type layering has significant difference is with confidence level
's.
Experimental group and the subject of control group are classified with AA, AG, GG type of UCP1 (rs1800592), and will
Subject recorded at 0 week with 12 weeks weight, BMI, waistline, waist-to-hipratio, body fat rate, body fat weight, interior fat weight, subcutaneous fat again
It records in table 5.
Table 5
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week
5 (Continued) of table
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week
5 (Continued) of table
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week
The AA type subject of comparative experiments group and control group is in 0 week and 12 weeks weight, BMI, waistline, waist-to-hipratio, body fat
Rate, body fat are heavy, interior fat is heavy and the numerical value of subcutaneous fat weight is known: waistline, the waist-to-hipratio of the AA type subject in experimental group
As the time of supplement bitter melon seed oil capsule increases and reduce, and the waistline of the AA type subject in control group, waist-to-hipratio are with then
Do not reduce；In addition, the body fat rate of the AA type subject in control group, body fat weight, interior fat weight and subcutaneous fat weight are with benefit
The time for filling olive oil capsule increases and has increase, body fat rate, the body fat weight, interior fat of the AA type subject in experimental group
Weight and subcutaneous fat weight do not increase then.
Also, the AG type subject of comparative experiments group and control group is in 0 week and 12 weeks weight, BMI, waistline, waist-to-hipratio, body
Rouge rate, body fat are heavy, interior fat is heavy and the numerical value of subcutaneous fat weight is known: the waistline of the AG type subject in experimental group is with benefit
The time for filling bitter melon seed oil capsule increases and has reduction, and waistline, the waist-to-hipratio of the AG type subject in control group do not drop then
It is low.
Furthermore the GG type subject of comparative experiments group and control group 0 week and 12 weeks weight, BMI, waistline, waist-to-hipratio,
Body fat rate, body fat are heavy, interior fat is heavy and the numerical value of subcutaneous fat weight is known: the body fat rate of the GG type subject in experimental group,
Body fat weight, interior fat weight and subcutaneous fat weight increase with the time of supplement bitter melon seed oil capsule and have increase, and in control group
GG type subject body fat rate, body fat weight, interior fat weight and subcutaneous fat weight do not increase then；In addition, it in control group
The waistline and waist-to-hipratio of GG type subject has reduction as the time of supplement olive oil capsule increases.
Therefore can be confirmed；Bitter melon seed oil has the body for the individual for being able to suppress the AA type for belonging to UCP1 (rs1800592)
Adipogenic ability.
Then, experimental group and the subject of control group are classified with TT the and CC type of β 3AR (rs4994), and will
Subject recorded at 0 week with 12 weeks weight, BMI, waistline, waist-to-hipratio, body fat rate, body fat weight, interior fat weight, subcutaneous fat again
It records in table 6.
Table 6
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week
6 (Continued) of table
Remarks: P-value* is to count to carry out with co-variation heteromerism (Covariance), under same time point, compares control
The knots modification of group and the intervention 4 weeks or 12 weeks of experimental group；
P-value** is when analyzed with duplicate measurements variance (Repeated measure ANOVA) in group with processing
Between (variation (increasing or decreasing) compares from 0 week to 12 week
The TT type subject of comparative experiments group and control group is in 0 week and 12 weeks weight, BMI, waistline, waist-to-hipratio, body fat
Rate, body fat are heavy, interior fat is heavy and the numerical value of subcutaneous fat weight is known: the waistline of the TT type subject in experimental group has with benefit
The time for filling bitter melon seed oil capsule increases and has reduction, and the waistline of the TT type subject in control group, waist-to-hipratio are with supplement olive
The time of olive oil capsule increases and has reduction；In addition, the interior fat weight of the TT type subject in control group is with supplement olive oil
The time of capsule increases and increases, and the TT type subject in experimental group does not increase with the time of supplement then and increased.
Also, the CC type subject of comparative experiments group and control group is in 0 week and 12 weeks weight, BMI, waistline, waist-to-hipratio, body
Rouge rate, body fat are heavy, interior fat is heavy and the numerical value of subcutaneous fat weight is known: body fat rate, the body of the CC type subject in control group
Rouge weight, interior fat weight and subcutaneous fat weight increase with the time of supplement olive oil capsule and are increased, and the CC type in experimental group
Subject does not increase with the time of supplement then and is increased.
Therefore can be confirmed；Bitter melon seed oil has the body fat for the individual for being able to suppress the CC type for belonging to β 3AR (rs4994)
The ability that fat is formed.It, can since the CC type of β 3AR (rs4994) is that this site β 3ADR (rs4994) is all mutated on homologue
It is higher that fat probability can occur, it is clear that bitter melon seed oil has antibody fat shape for the overweight people of β 3ADR (rs4994) all mutation
At ability.Therefore, bitter melon seed oil can apply to as the preparation for inhibiting body fat formation, and then can be with a variety of different dosage forms shapes
Formula is applied to take in the health food or drink of various functionals for user, and because bitter melon seed oil will not be to human body painstaking effort
Pipe and liver cause to bear, and can reduce doubt of the user for product safety.
In conclusion it is as listed above for embodiment in illustrated and specifically describe the contents of the present invention, so
And the present invention is not only defined in these embodiments.Persond having ordinary knowledge in the technical field of the present invention should be bright
It is white: without departing from the spirit and scope of the present invention, when various change and modification can be carried out again；For example, by previous embodiment
In illustrated by each technology contents be combined or change and become new embodiment, these embodiments are also considered as this certainly
Content belonging to inventing.Therefore, the range to be protected of this case also includes aftermentioned claim and its range that is defined.
Claims (10)
1. the purposes that bitter melon seed oil is used to prepare antibody Adipogenesis preparation, which is characterized in that its be bestow an effective dose it
Bitter melon seed oil is to required individual；Wherein the individual makes a variation with specific ob gene.
2. the purposes that bitter melon seed oil according to claim 1 is used to prepare antibody Adipogenesis preparation, which is characterized in that institute
The effective dose system stated is between 0.01 to 0.5 gram of bitter melon seed oil/individual kilogram weight/day range.
3. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil described in claim 1, which is characterized in that described
Specific ob gene be UCP1 gene or β 3ADR gene.
4. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil described in claim 1, which is characterized in that described
Bitter melon seed oil be able to suppress the generation of hungry plain (Ghrelin).
5. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil described in claim 1, which is characterized in that described
Bitter melon seed oil can promote the generation of adrenaline (adrenaline) and norepinephrine (noradrenaline).
6. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil described in claim 1, which is characterized in that described
The individual be the mankind.
7. the purposes that bitter melon seed oil is used to prepare antibody Adipogenesis preparation, which is characterized in that the antibody Adipogenesis preparation into
One step includes at least one in additive, carrier, excipient, diluent and they's combination.
8. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil described in claim 1, which is characterized in that described
Bitter melon seed oil content be 5wt%~100wt% range.
9. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil as claimed in claim 7, which is characterized in that described
Excipient by lactose, sucrose, mannitol, sorbierite, cornstarch, wheaten starch, rice starch, potato starch, bright
Glue, bassora gum, and combinations thereof in any one or more constituted.
10. being used to prepare the purposes of antibody Adipogenesis preparation according to bitter melon seed oil as claimed in claim 7, which is characterized in that institute
The dosage form system for the antibody Adipogenesis preparation stated be selected from solution, emulsion, suspension, powder, pastille, pill, mouth containing ingot, tablet,
It is any in chewing glue and capsule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107100847 | 2018-01-10 | ||
| TW107100847A TWI643630B (en) | 2018-01-10 | 2018-01-10 | Use of bitter gourd seed oil for preparing antibody fat forming preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109846040A true CN109846040A (en) | 2019-06-07 |
Family
ID=65431609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811635899.9A Pending CN109846040A (en) | 2018-01-10 | 2018-12-29 | Use of balsam pear seed oil for preparing anti-body fat forming preparation |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109846040A (en) |
| TW (1) | TWI643630B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109699756A (en) * | 2017-02-02 | 2019-05-03 | 中创寰宇生物科技有限责任公司 | Use of balsam pear seed oil for producing a composition for simulating sports effects |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008055363A1 (en) * | 2006-11-10 | 2008-05-15 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon, bitter melon and omega-3 fatty acids |
| CN102551046A (en) * | 2011-12-16 | 2012-07-11 | 无限极（中国）有限公司 | Natural health composition for weight reduction and application of same |
| CN103834739A (en) * | 2014-03-13 | 2014-06-04 | 上海中优门诊部有限公司 | Method for assessing lipid metabolism type obese gene constitution |
| CN105132146A (en) * | 2015-09-24 | 2015-12-09 | 全椒县尹氏油脂有限公司 | Extraction method of bitter melon seed oil |
| CN105623844A (en) * | 2016-03-23 | 2016-06-01 | 深圳市先康达生物科技有限公司 | Balsam pear seed oil, extraction method therefor and application thereof |
| CN106086222A (en) * | 2016-08-24 | 2016-11-09 | 厦门美因生物科技有限公司 | Motion detecting and evaluating genes method and system based on qPCR typing method |
-
2018
- 2018-01-10 TW TW107100847A patent/TWI643630B/en active
- 2018-12-29 CN CN201811635899.9A patent/CN109846040A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008055363A1 (en) * | 2006-11-10 | 2008-05-15 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon, bitter melon and omega-3 fatty acids |
| CN102551046A (en) * | 2011-12-16 | 2012-07-11 | 无限极（中国）有限公司 | Natural health composition for weight reduction and application of same |
| CN103834739A (en) * | 2014-03-13 | 2014-06-04 | 上海中优门诊部有限公司 | Method for assessing lipid metabolism type obese gene constitution |
| CN105132146A (en) * | 2015-09-24 | 2015-12-09 | 全椒县尹氏油脂有限公司 | Extraction method of bitter melon seed oil |
| CN105623844A (en) * | 2016-03-23 | 2016-06-01 | 深圳市先康达生物科技有限公司 | Balsam pear seed oil, extraction method therefor and application thereof |
| CN106086222A (en) * | 2016-08-24 | 2016-11-09 | 厦门美因生物科技有限公司 | Motion detecting and evaluating genes method and system based on qPCR typing method |
Non-Patent Citations (3)
| Title |
|---|
| GOU-CHUN CHEN等: ""The anti-adiposity effect of bitter melon"", 《LIPIDS IN HEALTH AND DISEASE》 * |
| PEI-HSUAN CHEN等: "Bitter Melon Seed Oil–Attenuated Body Fat Accumulation in Diet-Induced Obese Mice Is Associated with cAMP-Dependent Protein Kinase Activation and Cell Death in White Adipose Tissue1-3", 《THE JOURNAL OF NUTRITION》 * |
| 徐丽: ""苦瓜籽油的超临界提取工艺及其减肥作用和机制的初步研究"", 《中国优秀硕博士学位论文全文数据库（硕士） 医药卫生科技辑》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109699756A (en) * | 2017-02-02 | 2019-05-03 | 中创寰宇生物科技有限责任公司 | Use of balsam pear seed oil for producing a composition for simulating sports effects |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI643630B (en) | 2018-12-11 |
| TW201929887A (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110097946B (en) | Diet recommendation method based on nutrient analysis | |
| Bui et al. | Pre-germinated brown rice reduced both blood glucose concentration and body weight in Vietnamese women with impaired glucose tolerance | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| CN104013698A (en) | Natto crataegus pinnatifida capsule with assistant blood fat reduction function and preparation method thereof | |
| CN101878906B (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| Juraschek et al. | Effects of lowering glycemic index of dietary carbohydrate on plasma uric acid levels: the OmniCarb randomized clinical trial | |
| CN102845749A (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| CN109699756A (en) | Use of balsam pear seed oil for producing a composition for simulating sports effects | |
| CN105029411A (en) | Chlorella meal replacement powder | |
| CN109350705A (en) | A kind of composition and application with blood-enriching face-nourishing and strengthen immunity effect | |
| CN111772022A (en) | Low-GI (glycemic index) health sugar as well as preparation method and application thereof | |
| CN105725187B (en) | A kind of hypoglycemic composition and its purposes for being used to prepare food and health food | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN109846040A (en) | Use of balsam pear seed oil for preparing anti-body fat forming preparation | |
| CN106135878A (en) | Jilin Radix Ginseng oligopeptide purposes in preparation improves the food with sexual function improving or health food | |
| CN108042739A (en) | It is a kind of to be used to prevent composition of diabetes and its preparation method and application | |
| CN108514114A (en) | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory | |
| CN100428951C (en) | Yuanhe tablet and process for preparing the same | |
| CN104173734B (en) | A kind of pharmaceutical composition for treating IGR and preparation method thereof | |
| CN103719866B (en) | A kind of composition and use thereof, preparation method with effect of weight reducing | |
| Gujarathi et al. | Managing Obesity Through Ayurveda | |
| Devaki et al. | Evaluation of supplementation of Bittergourd fermented beverage to diabetic subjects | |
| CN108404088A (en) | Turbid, supplementing qi and nourishing yin Chinese medicine and preparation method thereof drops in a kind of heat-clearing | |
| Widyasari et al. | Vegetables Consumption Before Carbohydrates Improves Daily Fiber Intake and Blood Sugar Levels in Patients With Type 2 Diabetes Mellitus | |
| CN111511372A (en) | Composition for preventing or alleviating non-alcoholic fatty liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210901 Address after: 477150 No. 297, Gongye Avenue, Dancheng County, Zhoukou City, Henan Province Applicant after: Henan Xinshi Biotechnology Co.,Ltd. Address before: 250000 road 917, Jingshi East Road, Licheng District, Jinan City, Shandong Province Applicant before: ZHONGCHUANG HUANYU BIOTECH LLC |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190607 |
|
| WD01 | Invention patent application deemed withdrawn after publication |